Tissue penetration of antimicrobials: Difference between revisions
From IDWiki
Content deleted Content added
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
!Blood |
!Blood |
||
!CNS |
!CNS |
||
!Vitreous |
|||
!Urine |
!Urine |
||
!Prostate |
!Prostate |
||
!Necrotic |
!Necrotic |
||
|- |
|- |
||
! colspan=" |
! colspan="8" |Antibiotics: β-Lactams |
||
|- |
|- |
||
| rowspan="3" |[[Penicillins]] |
| rowspan="3" |[[Penicillins]] |
||
| Line 15: | Line 16: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" |– |
| style="text-align:center" |– |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| Line 22: | Line 24: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| Line 29: | Line 32: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | +† |
| style="text-align:center" | +† |
||
| Line 37: | Line 41: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" |– |
| style="text-align:center" |– |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| Line 44: | Line 49: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" |– |
| style="text-align:center" |– |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| Line 51: | Line 57: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | +† |
| style="text-align:center" | +† |
||
| Line 58: | Line 65: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| Line 65: | Line 73: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| Line 73: | Line 82: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" |– |
| style="text-align:center" |– |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| Line 80: | Line 90: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| Line 88: | Line 99: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
|- |
|- |
||
! colspan=" |
! colspan="8" |Antibiotics: Non-β-Lactams |
||
|- |
|- |
||
|[[Aminoglycosides]] |
|[[Aminoglycosides]] |
||
| Line 98: | Line 110: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| Line 106: | Line 119: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| Line 114: | Line 128: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" |–? |
| style="text-align:center" |–? |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| Line 122: | Line 137: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| Line 130: | Line 146: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" |– |
| style="text-align:center" |– |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| Line 138: | Line 155: | ||
| + |
| + |
||
|– |
|– |
||
| |
|||
| + |
| + |
||
| |
| |
||
| Line 146: | Line 164: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" |– |
| style="text-align:center" |– |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| Line 154: | Line 173: | ||
| style="text-align:center" |– |
| style="text-align:center" |– |
||
| style="text-align:center" |– |
| style="text-align:center" |– |
||
| |
|||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| style="text-align:center" |– |
| style="text-align:center" |– |
||
| Line 162: | Line 182: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| Line 170: | Line 191: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| Line 178: | Line 200: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| Line 186: | Line 209: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" |– |
| style="text-align:center" |– |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| Line 193: | Line 217: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
|- |
|- |
||
! colspan=" |
! colspan="8" |Antivirals |
||
|- |
|||
| |
|||
|[[acyclovir]] / [[valacyclovir]] |
|||
| |
|||
| |
|||
| + |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
| |
|||
|[[ganciclovir]] |
|||
| |
|||
| |
|||
| + |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
| |
|||
|[[foscarnet]] |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
! colspan="8" |Antifungals |
|||
|- |
|- |
||
|[[Azoles]] |
|[[Azoles]] |
||
| Line 203: | Line 257: | ||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| |
|||
| style="text-align:center" | |
| style="text-align:center" | |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| Line 211: | Line 266: | ||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| |
|||
| style="text-align:center" |– |
| style="text-align:center" |– |
||
| style="text-align:center" | |
| style="text-align:center" | |
||
| Line 219: | Line 275: | ||
!Blood |
!Blood |
||
!CNS |
!CNS |
||
! |
|||
!Urine |
!Urine |
||
!Prostate |
!Prostate |
||
Revision as of 17:11, 13 February 2021
Summary
| Class | Antimicrobial | Blood | CNS | Vitreous | Urine | Prostate | Necrotic |
|---|---|---|---|---|---|---|---|
| Antibiotics: β-Lactams | |||||||
| Penicillins | β-lactamase inhibitors | – | |||||
| ampicillin | + | – | |||||
| piperacillin-tazobactam | +† | ||||||
| Cephalosporins | first-generation cephalosporins | – | – | ||||
| second-generation cephalosporins | – | ||||||
| third-generation cephalosporins | +† | ||||||
| cefepime | + | ||||||
| ceftazidime | + | + | |||||
| Cephamycins | cephamycins | – | |||||
| cefoxitin | – | ||||||
| Carbapenems | imipenem | + | |||||
| Antibiotics: Non-β-Lactams | |||||||
| Aminoglycosides | – | ||||||
| Chloramphenicol | chloramphenicol | + | |||||
| Fluoroquinolones | –? | + | + | ||||
| Fosfomycin | fosfomycin | + | |||||
| Lincosamides | clindamycin | – | + | ||||
| Lipopeptides | daptomycin | + | – | + | |||
| Macrolides | macrolides | – | + | ||||
| Nitrofurans | nitrofurantoin | – | – | + | – | – | |
| Nitroimidazoles | metronidazole | + | |||||
| Rifamycins | rifampin | + | |||||
| Sulfonamides | trimethoprim-sulfamethoxazole | + | |||||
| Tetracyclines | tetracyclines | – | + | ||||
| doxycycline | + | + | |||||
| Antivirals | |||||||
| acyclovir / valacyclovir | + | ||||||
| ganciclovir | + | ||||||
| foscarnet | |||||||
| Antifungals | |||||||
| Azoles | fluconazole | + | |||||
| Echinocandins | + | – | |||||
| Class | Antimicrobial | Blood | CNS | Urine | Prostate | Necrotic | |
- † if inflammation present
Prostate
- Poorly penetrated by most antibiotics
- Penetration is higher with a high concentration gradient, high lipid solubility, low degree of ionization, high dissociation constant, low protein binding, and small molecular size
- Fluoroquinolones are the mainstay of therapy, though there is increasing resistance
- TMP-SMX often used, though conflicting data about its penetration into the prostate
- Minocycline, doxycycline, and macrolides achieve high levels in the prostate but are rarely indicated for the causative organisms
- Third-generation cephalosporins and carbapenems can be used
- Piperacillin, aztreonam, imipenem, and some aminoglycosides are likely useful
Bone
- Essentially all antibiotics achieve similar bone-to-serum levels, with the exception of oral β-lactams which nevertheless have no worse outcomes1
References
- ^ Cornelia B. Landersdorfer, Jürgen B. Bulitta, Martina Kinzig, Ulrike Holzgrabe, Fritz Sörgel. Penetration of Antibacterials into Bone. Clinical Pharmacokinetics. 2009;48(2):89-124. doi:10.2165/00003088-200948020-00002.